Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma

Blood

Volumn 121, Issue 5, 2013, Pages 745-751

  Rubenstein, James L ^a,b,k   Li, Jing ^c   Chen, Lingjing ^a   Advani, Ranjana ^d   Drappatz, Jan ^e   Gerstner, Elizabeth ^f   Batchelor, Tracy ^f   Krouwer, Hendrikus ^g   Hwang, James ^h   Auerback, Glenna ^a,b   Kadoch, Cigall ^a   Lowell, Clifford ⁱ   Munster, Pamela ^a,b   Cha, Soonmee ^b,j   Shuman, Marc A ^a,b   Damon, Lloyd E ^a,b  

^a Department of Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GENENTECH INC   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h Biostatistics and Computational Biology Core   (United States)

ⁱ Department of Laboratory Medicine ^*  (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Phase I study showed that intraventricular rituximab plus methotrexate is feasible and active in the treatment of refractory CNS lymphoma

Indexed keywords

CIMETIDINE; CYTARABINE; DIPHENHYDRAMINE; FAMOTIDINE; FOLINIC ACID; METHOTREXATE; PARACETAMOL; RITUXIMAB; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BRAIN TISSUE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CATARACT; CHILL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEASIBILITY STUDY; FEMALE; GAIT DISORDER; HUMAN; LYMPHOCYTOPENIA; MALE; MONOTHERAPY; MUSCLE RIGIDITY; MUSCLE WEAKNESS; NEUTROPENIA; OCULOMOTOR NERVE DISEASE; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT OUTCOME;

EID: 84873544339     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-440974     Document Type: Article

References (31)

1. Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol. 2004;15(1):129-133. (Pubitemid 38139614)
2. Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol. 2011;90(7):809-818.
3. Yamamoto W, Tomita N, Watanabe R, et al. Central nervous system involvement in diffuse large B-cell lymphoma. Eur J Haematol. 2010;85(1):6-10.
4. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003; 101(2):466-468. (Pubitemid 36077565)
5. Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011;76(10):929-930.
6. Duchnowska R, Dziadziuszko R, Czartoryska- Arlukowicz B, et al. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res Treat. 2009;117(2): 297-303.
7. Musolino A, Ciccolallo L, Panebianco M, et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer. 2011;117(9):1837-1846.
8. Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007;25(11):1350-1356. (Pubitemid 46706881)
9. Bonney DK, Htwe EE, Turner A, et al. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant. Pediatr Blood Cancer. 2012;58(3):459-461.
10. Jaime-Pérez JC, Rodriguez-Romo LN, Gonzalez-Llano O, Chapa-Rodriguez A, Gomez-Almaguer D. Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy. Br J Haematol. 2009;144(5): 794-795.
11. Villela L, Garcia M, Caballero R, Borbolla-Escoboza JR, Bolanos-Meade J. Rapid complete response using intrathecal rituximab in a patient with leptomeningeal lymphomatosis due to mantle cell lymphoma. Anticancer Drugs. 2008;19(9):917-920.
12. Liu CY, Teng HW, Lirng JF, Chiou TJ, Chen PM, Hsiao LT. Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab. Leuk Lymphoma. 2008;49(10):2018-2021.
13. van de Glind G, de Graaf S, Klein C, Cornelissen M, Maecker B, Loeffen J. Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system. Pediatr Blood Cancer. 2008;50(4):886-888. (Pubitemid 351354810)
14. Antonini G, Cox MC, Montefusco E, et al. Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma. J Neurooncol. 2007;81(2):197-199. (Pubitemid 44963979)
15. Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica. 2004;89(6):753-754. (Pubitemid 38828486)
16. Dujmovic D, Aurer I, Radman I, et al. Addition of rituximab to high-dose methotrexate-based chemotherapy improves survival of adults with Burkitt lymphoma/leukemia. Acta Haematol. 2012; 127(2):115-117.
17. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-2581. (Pubitemid 38758544)
18. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009;101(10):708-720.
19. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034-5043. (Pubitemid 46224010)
20. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21(21): 3940-3947. (Pubitemid 46606207)
21. Bomgaars L, Geyer JR, Franklin J, et al. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol. 2004; 22(19):3916-3921. (Pubitemid 41079873)
22. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non- Hodgkin's lymphoma. Ann Oncol. 1998;9(9):995-1001. (Pubitemid 28496709)
23. Igarashi T, Kobayashi Y, Ogura M, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol. 2002;13(6):928-943. (Pubitemid 34752689)
24. Tobinai K, Igarashi T, Itoh K, et al. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol. 2004; 15(5):821-830. (Pubitemid 38714746)
25. Czyzewski K, Styczynski J, Krenska A, et al. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder [published online ahead of print August 31, 2012]. Leuk Lymphoma.
26. Pulido JS, Bakri SJ, Valyi-Nagy T, Shukla D. Rituximab penetrates full-thickness retina in contrast to tissue plasminogen activator control. Retina. 2007;27(8):1071-1073. (Pubitemid 350304009)
27. Zigova T, Pencea V, Wiegand SJ, Luskin MB. Intraventricular administration of BDNF increases the number of newly generated neurons in the adult olfactory bulb. Mol Cell Neurosci. 1998; 11(4):234-245. (Pubitemid 28361411)
28. Gustafsson E, Lindvall O, Kokaia Z. Intraventricular infusion of TrkB-Fc fusion protein promotes ischemia-induced neurogenesis in adult rat dentate gyrus. Stroke. 2003;34(11):2710-2715. (Pubitemid 37392772)
29. Figlewicz DP, Szot P, Chavez M, Woods SC, Veith RC. Intraventricular insulin increases dopamine transporter mRNA in rat VTA/substantia nigra. Brain Res. 1994;644(2):331-334. (Pubitemid 24127991)
30. Pencea V, Bingaman KD, Wiegand SJ, Luskin MB. Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J Neurosci. 2001;21(17):6706-6717. (Pubitemid 32781115)
31. Nagahara AH, Merrill DA, Coppola G, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med. 2009;15(3):331-337.